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Abstract The cap-binding initiation factor 4E (eIF4E) is 
regulated by phosphorylation and by the inhibitory binding 
protein 4E-BPl. Here we show that insulin-induced phosphoryl- 
ation of eIF4E is not significantly affected by rapamycln, but is 
sensitive to wortmannin, which inhibits phosphatidylinositol 3’- 
kinase and blocks the activation of MAP kinase. Since 
PD098059, an inhibitor of MAP kinase activation, also blocks 
insulin-induced phosphorylation of eIF4E, the MAP kinase 
pathway seems to mediate this effect. Phosphorylated eIF4E can 
still bind to 4E-BPl. These data illustrate that (i) distinct 
signalling pathways mediate the phosphorylation of eIF4E and 
4E-BP1 and (ii) phosphorylation of eIF4E, unlike that of 4E- 
BPl, does not lead directly to the release of 4E-BPl. 
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1. Introduction 
Initiation factor 4E (eIF4E) plays a key role in mRNA 
translation in eukaryotic cells by binding the 5’-cap structure 
(7-methylguanosine) which is present at the 5’-end of all cel- 
lular cytoplasmic mRNAs [l-3]. eIF4E undergoes phospho- 
rylation at a single major site now identified as Ser-209 close 
to the C-terminus of this 216 amino acid protein [4,5]. Phos- 
phorylation of eIF4E is increased under a variety of condi- 
tions where rates of translation are enhanced. These include 
treatment of cells with insulin or growth factors or other 
mitogens (reviewed in [6-81). Despite the well-characterised 
correlation between eIF4E phosphorylation and increased 
rates of translation, it is still not clear how phosphorylation 
influences the biological activity of eIF4E, although it has 
been reported that phosphorylated eIF4E has a higher affinity 
for the mRNA cap than does its nonphosphorylated counter- 
part [9]. It is also the case that phosphorylated eIF4E seems to 
be associated preferentially with other translation factors, i.e. 
the other components of the eIF4F complex [2,3,10]. Earlier 
studies addressing the role of eIF4E phosphorylation em- 
ployed mutants of eIF4E in which the residue then considered 
to be the site of phosphorylation (Ser-53) was altered to Ala 
to preclude phosphorylation [ll-131. These results are now 
clearly invalid since this is not the main site of phosphoryla- 
tion. 
Two additional proteins which interact with eIF4E have 
recently been discovered. These are termed 4E-BP1 and 4E- 
BP2 (eIF4E binding proteins 1 and 2). Each inhibits cap-de- 
pendent mRNA translation implying that they block the func- 
tion of eIF4E in peptide-chain initiation [14]. 4E-BP1 (also 
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known as PHAS-I) is a phosphoprotein whose state of phos- 
phorylation increases in response to insulin [l&18] or insulin- 
like growth factor-l (IGF-1 [19]). This causes its dissociation 
from eIF4E and should result in the alleviation of the inhibi- 
tion of eIF4E. Recent work from the group of Sonenberg 
indicates that 4E-BP1 prevents the assembly of the eIF4F 
complex and hence efficient translation initiation [20,21]. 
The insulin- or IGF-l-induced phosphorylation of 4E-BP1 
has been shown, in several cell-types, to be inhibited by the 
immunosuppressant rapamycin, a specific inhibitor of the sig- 
nalling pathway which leads to activation of the p70 riboso- 
ma1 protein S6 kinase (p70S6k) [17-19,221. Consistent with its 
effect on 4E-BPl, rapamycin blocks translation in mammalian 
cells and in Saccharomyces cerevisiae [22,23]. 
We have examined the signal transduction pathway which 
leads to the phosphorylation of eIF4E. Our data indicate that 
eIF4E phosphorylation is not blocked by rapamycin, while 
the phosphorylation of 4E-BP1 is blocked by this drug, as 
in other cell types. Thus, the phosphorylation of the two pro- 
teins in response to insulin is mediated via distinct signalling 
pathways. Furthermore, eIF4E phosphorylation is blocked by 
interventions which prevent activation of the MAP kinase 
pathway, indicating that eIF4E is a target for signalling via 
this pathway. 
2. Materials and methods 
2.1. Chemicals and biochemicals 
m7GTP-Sepharose was from Pharmacia Biotech Inc. [y-32P]ATP 
was purchased from Arnersham plc. Chinese hamster ovary 
(CH0.T) cells were kindly provided by Dr. L. Ellis (Houston, TX). 
Materials for tissue culture were obtained from Gibco Life Technol- 
ogies, Inc. Microcystin, wortmannin, rapamycin and CHAPS were 
from Calbiochem. Unless otherwise stated, all other reagents were 
from Sigma. Antiserum to 4E-BP1 was generously provided by Dr. 
T.A. Diasle and Professor R.M. Denton (University of Bristol). 
PD09805?J-was a kind gift from Parke-Davis (through Dr. A.R. Sal- 
tie]). 
2.2. Cell culture and treatment of cells 
CH0.T cells were grown and maintained in culture as described 
previously [24]. For experiments, plated cells were grown to 80% 
confluence in medium containing 10% [v/v] serum and then starved 
of serum for 24 h prior to treatment and extraction. Treatments with 
agonists and/or inhibitors of signal transduction were as described in 
each figure legend. Cells were then washed and extracts prepared as 
described in [24]. 
2.3. Electrophoresis and immunoblotting 
SDS-polyacrylamide gel electrophoresis and Western blotting were 
performed as described earlier [25]. Blots were developed using the 
Enhanced Chemiluminescence kit (Amersham plc). Isoelectric focus- 
ing of eIF4E was performed as described [5,26] using Ampholines 
(Pharmacia) in the pH range 3.5510. 
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2.J. Isolation of initiation factors 
:IF4E was isolated as described previously for analysis by isoelec- 
tric focusing [5]. In the case of SDS-PAGE, proteins were removed 
from the m7GTP-Sepharose matrix by boiling in concentrated SDS 
sample buffer. Immunoprecipitation of 4E-BP1 was as described by 
Dlggle et al. [27]. 
band shift for, and therefore the activation of, p70 S6 kinase 
(Fig. 1C). 
3.2. Rapamycin does not prevent phosphorylation of elF-4E 
2. Assessment of the activation of protein kinases 
MAP kinase was assayed using the peptide substrate ‘Thr-669’ ex- 
ac ly as described previously [28] except that crude extracts rather 
th tn immunoprecipitates were used. The activation state of p70 S6 
ki lase was assessed by means of its migration on SDS-PAGE, where 
in reased phosphorylation of the enzyme, which leads to its activa- 
tic n, causes it to migrate more slowly. The method has been described 
pr viously [29]. 
In order to test whether rapamycin also blocks the phos- 
phorylation of eIF4E which occurs in these cells in response 
to insulin [26], the phosphorylation state of eIF4E was as- 
sessed by the isoelectric focusing/immunoblotting procedure 
that we have described elsewhere [26] (Fig. 1 D). Insulin results 
in a rapid (within 7.5 min) and marked increase in the state of 
phosphorylation of eIF4E and this increase was not affected 
by rapamycin. 
Thus, the phosphorylation of eIF4E in response to insulin 
appears to involve a distinct signalling pathway from that 
leading to the phosphorylation of 4E-BPl. The pathway 
which regulates eIF4E phosphorylation is therefore also dis- 
tinct from that leading to activation of p70 S6k. These data 
also imply that the increase in the phosphorylation state of 
eIF4E induced by insulin is not merely a consequence of the 
dissociation of eIF4E from 4E-BPl, which is a possible mech- 
anism. Rather, it is due to other events, e.g. the activation of 
an eIF4E kinase such as that recently described by the group 
of Damuni [31]. 
3. Results 
3. ‘. Interaction of eIF4E with IE-BP1 in CHO. T cells 
[n order to examine the degree of association between 4E- 
BP1 and eIF4E, cell extracts were processed to isolate eIF4E 
arld associated 4E-BP1 by affinity chromatography on 
m GTP-Sepharose. The resulting samples were then subjected 
to SDS-PAGE and immunoblotting. Insulin caused a marked 
decrease in the amount of 4E-BP1 recovered after this step 
(I ig. 1A). Rapamycin blocked the dissociation of 4E-BP1 in- 
dt.ced by insulin (data not shown), as has been reported for 
ot ler cell types [14,17-19,22,30]. On SDS-PAGE, 4E-BP1 mi- 
gr ttes as a doublet (Fig. 1B). A third, faster migrating species 
w;s also visible in some experiments. When 4E-BP1 was im- 
mimoprecipitated from control and insulin-treated cells it 
could be seen that there was an apparent shift in its migration 
uIon insulin treatment (as reported earlier [17-19,221, and 
apparently resulting from its phosphorylation). This shift 
w. s entirely blocked by rapamycin, which also blocked the 
A 
B 
3.3. Phosphorylation of elF-4E by insulin or serum is blocked 
by wortmannin 
Other pathways which could lead to enhanced phosphoryl- 
ation of eIF4E include the MAP kinase pathway which is also 
activated by insulin in CH0.T cells [24,28]. As we have re- 
ported previously, the activation of MAP kinase is substan- 
tially blocked by wortmannin [28], which is a potent and 
selective (although not absolutely specific) inhibitor of phos- 
phatidylinositol-3’-kinase (Pl 3’-kinase) [32]. 
C 
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Fik. 1. Effects of insulin and rapamycin on eIF4E and 4E-BPl. In each panel, serum-starved CH0.T cells were used to prepare extracts for 
andysis. Each panel shows data typical of those obtained from at least three independent experiments. (A) Cells were incubated for 1Omin in 
the absence (C) or presence (I) of 2.5 nM insulin. eIF4E was isolated from the cell extracts by affinity chromatography on m7GTP-Sepharose. 
Samples were analysed by SDS-PAGE followed by Western blotting using an affinity-purified anti-eIF4E antibody and an anti-4E-BP1 anti- 
serum. (B,C) Cells were incubated for 30 min in the presence of DMSO carrier (lanes 1,3) or 20 nM rapamycin (lanes 2,4) before a further 5 
min incubation with no addition (lanes 1,2) or 10 nM insulin (lanes 3,4). Cell extracts were prepared and used both to immunoprecipitate 4E- 
BP1 (B) and to analyse the band shift for p7OS6 kinase (C). Both panels show Western blots from SDS-PA gels. (D) CH0.T cells were incu- 
bated for 30 min in the presence of DMSO (upper blot) or 20 nM rapamycin (lower blot) before being challenged with 10 nM insulin for vary- 
ing times, as indicated. eIF4E was isolated as before and analysed by isoelectric focusing (IEF) followed by Western blotting. The direction of 
electrophoresis is indicated. 
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Fig. 2. Increased phoshorylation of eIF4E is mediated by the MAP kinase pathway. (A) Serum-starved CH0.T cells were incubated for 15 min 
in the presence of DMSO carrier (lanes 14) or 100 nM wortmannin (lanes 5-Q before challenging for a further 10 min with no addition 
(lanes 1,5), 10 nM insulin (lanes 2,6), 1 uM PMA (lanes 3,7) or 10% (v/v) foetal calf serum (lanes 48). eIF4E was isolated from cell extracts 
(see Fig. 1) and analysed by IEF followed by Western blotting with an affinity-purified anti-eIF4E antibody. The direction of electrophoresis is 
indicated. (B) Cells were incubated for 1 h in the presence of DMSO carrier (lanes 1,3,5) or 50 uM PD098059 (lanes 2,4,6) before challenging 
for a further 10 min with no addition (lanes 1,2), or with insulin at 2 nM (lanes 3,4) or 5 nM (lanes 5,6). Cell extracts were used to perform 
IEF for eIF4E as described above. (C) Cells were incubated for 1 h in the presence of DMSO carrier (lanes l-3) or 50 uM PD098059 (lanes 
46) before challenging for a further 10 min with no addition (lanes 1,4), or with insulin at 2 nM (lanes 2,5) or 5 nM (lanes 3,6). Cell extracts 
were used to analyse the association of 4E-BP1 with eIF4E, as described in the legend to Fig. 1. 
Wortmannin largely blocked the increase in phosphoryla- 
tion of eIF4E induced by insulin, phorbol ester or serum (Fig. 
2A). This finding suggests that the phosphorylation of eIF4E 
requires a signalling pathway involving Pl 3’-kinase. Pl 3’- 
kinase is thought to lie upstream of p70 S6 kinase, but the 
involvement of this pathway in eIF4E phosphorylation was 
ruled out by the data described above. 
3.4. Eflect of inhibitors of the MAP kinase cascade 
The above data obtained with wortmannin were consistent 
with the idea that the increase in the phosphorylation of 
eIF4E is mediated via the MAP kinase signalling pathway. 
However, since other signalling pathways are also down- 
stream of Pl 3’-kinase (e.g. protein kinase B, PKB [33,34]), 
it was important to test directly the role of the MAP kinase 
pathway. To do this we made use of a recently described 
inhibitor (PD098059) of the activation of the MAP kinase 
kinase (MEK) which blocks the activation of MAP kinase 
in a variety of cell types [19,35-371. This compound also 
blocks activation of MAP kinase in CH0.T cells provided 
low concentrations of insulin are used. In five separate experi- 
ments, PD098059 decreased the activity of MAP kinase seen 
in response to 2 or 5 nM insulin to 7.6 f 3.4 or 29.2 f 8.7%, 
respectively, of the values seen with hormone alone. Other 
workers have also reported that PD098059 fails to block com- 
pletely the activation of MAP kinase in response to high doses 
of agonist [35,36]. 
PD098059 also inhibited the insulin-induced increase in 
eIF4E phosphorylation seen at such doses of insulin (Fig. 
2B). It should be noted that at higher insulin concentrations, 
where PD098059 only partly blocks activation of MAP ki- 
nase, the effect on eIF4E phosphorylation was also only par- 
tial, lending further weight to the idea that eIF4E lies down- 
stream of MAP kinase. 
Although PD098059 tended to increase the amount of 4E- 
BP1 associated with eIF4E in control cells, it had no effect 
whatsoever on the ability of insulin to induce the release of 
4E-BP1 from eIF4E (Fig. 2C). Thus, the effect of this com- 
pound on the insulin-induced phosphorylation of eIF4E can- 
not be ascribed to impaired dissociation of 4E-BP1 (and hence 
possible occlusion of the phosphorylation site in eIF4E). The 
increased association of 4E-BP1 with eIF4E in control cells 
treated with PD098059 was associated with a rise in the re- 
lative proportion of the protein in the fastest-migrating, and 
presumably least phosphorylated, form. The observation that 
PD098059 did affect the basal level of association of 4E-BP1 
with eIF4E was surprising given an earlier report that this 
compound did not influence this or the phosphorylation state 
of 4E-BP1 in 3T3-Ll adipocytes [18]. 
The simplest explanation for these observations would be 
that eIF4E itself is a substrate for either MAP kinase or an- 
other kinase in this pathway. We therefore tested the abilities 





Fig. 3. Analysis of the phosphorylation state of eIF4E bound to 
4E-BPl. CH0.T cell extracts were used to isolate either eIF4E by 
affinity chromatography (lane 1) or 4E-BP1 by immunoprecipitation 
(lane 2). In both cases, proteins were eluted from the washed Se- 
pharose pellets by mixing with urea and concentrated IEF sample 
buffer (see Section 2). Samples were analysed by IEF and Western 
blotting using an affinity purified anti-eIF4E antibody. The direction 
of electrophoresis is indicated. 
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MAP kinase to phosphorylate purified eIF4E. The latter two 
enzymes are MAP kinase-activated protein kinase-1 (an iso- 
form of p90 ribosomal protein S6 kinase [38]) and MAP ki- 
nase-activated protein kinase-2 (which may lie on a separate 
signalling pathway in vivo [39]). None of these enzymes was 
able to phosphorylate eIF4E purified from rabbit reticulo- 
qres, although each was active as assessed using standard 
su xtrates (data not shown). 
3. ‘. Phosphorylated e/F-4E still interacts with IE-BP1 
To test whether phosphorylated eIF4E can still bind to 4E- 
Bl’l, 4E-BP1 immunoprecipitates were subjected to isoelectric 
fo :using analysis and immunoblotting using an anti-eIF4E 
ar tibody (Fig. 3). These data indicate that phosphorylated 
eI 74E can bind to 4E-BP1 and thus that the phosphorylation 
of elF-4E does not play a major role in the regulation of this 
in eraction. 
4. Discussion 
The data described here show that the insulin-induced 
phosphorylation of eIF4E is mediated by a signalling pathway 
distinct from that which leads to the dissociation of 4EBPl 
frc .rn eIF4E. The latter event involves the phosphorylation of 
4E -BP1 [14,30] and is blocked by rapamycin [17-19,221. Mor- 
le! and Pain [8] have also recently reported that rapamycin 
fal;ed to block the increased phosphorylation of eIF4E 
(termed eIF4cx in their paper) which is induced following 
thl activation of T-lymphocytes. 
1ur findings strongly point to a key role for the MAP 
kinase pathway in mediating the insulin-induced increase in 
eIV4E phosphorylation. The specific inhibitor of the activa- 
tic n of MAP kinase kinase (PD098059), which blocked the 
sti:nulation of MAP kinase by the concentrations of insulin 
usc,d here, also completely eliminated the increase in eIF4E 
ph xphorylation. Since none of the known kinases which are 
ac: ivated downstream of MAP kinase kinase (i.e. MAP kinase 
an 1 MAP kinase-activated kinases-I and -2) was able to 
ph xphorylate eIF4E, it is likely that a further protein kinase, 
wt ose activation is linked to the MAP kinase pathway, medi- 
ate J this effect. As the activation of MAP kinase is linked via 
R2.f and MAP kinase kinase to Ras, our data are entirely 
co:uistent with earlier findings pointing to a role for Ras in 
mrdiating the phosphorylation of eIF4E [40,41]. In particular, 
a I ominant negative mutant of Ras was shown to block the 
ne’ ve growth factor-induced phosphorylation of eIF4E is 
PC 12 cells [40]. Makkinje et al. [31] have shown that an in- 
sul n-stimulated protamine kinase can phosphorylate eIF4E at 
thr appropriate site (Ser-209 [4,5]) in vitro. Its mode of acti- 
val ion by insulin is so far unknown: one might speculate that 
thi ‘I kinase is activated by insulin in a Ras- and MAP kinase- 
de] lendent manner. 
1 )ur observation that PD098059 affects the phosphorylation 
of IE-BPl, and its association with eIF4E, in our hands sug- 
gesa that there is some input from the MAP kinase pathway 
to :he regulation of this protein at least in CH0.T cells. In 
adctition, the large increase in the amount of 4E-BP1 asso- 
cia,ed with eIF4E in PD098059-treated cells (Fig. 2C) also 
ind tcates that even in serum-starved CH0.T cells, only a small 
proportion of the elF-4E is bound to 4E-BPl. This is an 
adT antage in separating the insulin-stimulated phosphoryla- 
tioll of elF-4E from the dissociation of the factor from 4E- 
BP1 ; it is even more unlikely that this latter event plays a part 
in the increase in phosphorylated eIF4E. 
It is thus clear that at least two distinct signalling pathways 
are involved in the control of the initiation of mRNA transla- 
tion, the MAP kinase pathway and that which includes p70 S6 
kinase [17-19,221. 
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